Lauren Kramer advises public and private companies, private equity firms, family offices and sovereign wealth funds in U.S. and cross-border acquisitions, divestitures, mergers, carve-outs, strategic investments and corporate governance matters.
Lawdragon Honors
| Honor | Year | Practice |
|---|---|---|
| The 2026 Lawdragon 500 X – The Next Generation | 2026 | M&A, Private Equity |
| The 2025 Lawdragon 500 X – The Next Generation | 2025 | M&A, Private Equity |
Kramer’s select representations include:
- Netflix in its proposed (but terminated) $82.7 billion acquisition of Warner Bros.
- Honeywell in its:
- $7.7 billion spin-off of Solstice Advanced Materials Inc.
- $4.95 billion acquisition of the global access solutions business of Carrier Global Corporation
- $1.3 billion acquisition of Sparta Systems from New Mountain Capital
- Berry Global Group, Inc. in its $37 billion merger with Amcor
- Keurig Dr Pepper in its strategic partnership and $300 million investment in La Colombe Coffee Roasters
- Activision Blizzard Inc. in its $75 billion acquisition by Microsoft Corporation
- Spotify Technology S.A. in its (i) acquisition of Chartable Holding Inc. and (ii) acquisition of Megaphone LLC from Graham Holdings
- Vital Proteins in its acquisition by Nestlé Health Science
- Mubadala Investment Company in its investment as part of a consortium of $2.25 billion in Waymo
- NXP Semiconductors N.V. in its:
- $1.8 billion acquisition of Marvell Technology Group Ltd.’s wireless connectivity portfolio
- proposed (but terminated) $47 billion acquisition by Qualcomm Incorporated
- Permira Funds in several transactions, including:
- the sale of its portfolio company LSNE to PCI Pharma Services
- its acquisition of a majority stake in Axiom
- its acquisition of a majority stake in Reformation
- its acquisition of a majority stake in Cielo, Inc. from Accel-KKR
- the $2.3 billion sale of its portfolio company Atrium Innovations to Nestlé S.A.
- Goldman Sachs & Co. as financial advisor in several transactions, including:
- Turning Point Therapeutics, Inc. in its $4.1 billion sale to Bristol-Myers Squibb Company
- Covetrus, Inc. in its $4 billion sale to funds affiliated with Clayton, Dubilier & Rice and TPG Capital